NCT06605404ClinicalTrials.gov
Pan-tumor MRD Study
Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer Biomarkers
باختصار
The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors. The information collected will be used to…
رصديةمطلوب 1,350 مشاركاً47 موقعاًدولة واحدة
الفئات
مسجَّلة في سجل واحد
- ClinicalTrials.govNCT06605404فتح هذا السجل في ClinicalTrials.govتمت المزامنة قبل شهرين
يمكن أن تُسجَّل دراسة واحدة في عدة سجلات. نعرضها مرة واحدة ونربط بكل سجل نحتفظ به.
تُعرض معلومات التجربة كما نشرها السجل، بلغتها الأصلية.
هل أنت مهتم بهذه الدراسة؟
تسجيل الدخول أو أنشئ حسابًا لتسجيل اهتمامك ومتابعة هذه الدراسة.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2024-09-20; recorded start 2025-01-08
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Not stated: Whether participants are randomly assigned is not stated in the registry recordNo allocation method is recorded
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Not stated: Whether the study is blinded is not stated in the registry recordNo masking information is recorded
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Not stated: No other studies from this sponsor are in this databaseCounted from the lead sponsor named in the record (Paradigm Health)
- Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
- The record lists 7 conditions.
- Lead sponsor type recorded as: industry.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
An exploratory-stage design for a study of this type, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation0/20
Allocation not stated in the record
- Blinding0/20
Masking not stated in the record
- Control arm0/15
No comparator arm stated in the record
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre5/8
Multi-centre: 2 sites
- Data monitoring committee0/7
No data monitoring committee stated
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A large study: 1,350 participants (target), run at 47 sites.
How this score is built
- Enrolment31/40
1,350 participants (target)
- Site count4/25
2 sites
- Country count0/15
Single country
- Planned duration10/10
Planned over about 88 months
- Sponsor scale0/10
Paradigm Health has led 1 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
ملخص
The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors. The information collected will be used to develop tests to better understand cancer, for example, to improve cancer detection and to assess the risk of cancer coming back. Participants will receive routine standard of care from their doctor and their involvement is expected to last for approximately five and a half (5.5) years.
الحالات
- Muscle Invasive Bladder Urothelial Carcinoma
- Esophageal Cancer
- Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
- Melanoma (Skin Cancer)
- NSCLC (Non-small Cell Lung Cancer)
- Pancreatic (Exocrine Only)
- Mix of Solid Tumors (MOST)
الأهلية
| الجنس | الجميع |
|---|---|
| الأعمار | 18 Years – لا حد أقصى |
| المتطوعون الأصحّاء | لا |
| طريقة أخذ العينات | NON_PROBABILITY_SAMPLE |
مجتمع الدراسة
Study participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors
الأهلية كما كُتبت في السجل
الأهلية في عبارات بسيطة
لم تُقسَّم معايير هذا السجل إلى عبارات منفصلة بعد. نص السجل أعلاه كامل وهو النسخة المُعتمَدة.
تصميم الدراسة
| نوع الدراسة | رصدية |
|---|---|
| المرحلة | غير مذكور في سجل السجل |
| التخصيص | غير مذكور في سجل السجل |
| نموذج التدخّل | غير مذكور في سجل السجل |
| الغرض الأساسي | غير مذكور في سجل السجل |
| التعمية | غير مذكور في سجل السجل |
| التجنيد | مطلوب 1,350 مشاركاً |
الجهة الراعية والمتعاونون
- Paradigm Health الجهة الراعية
الأذرع والتدخلات
- Muscle Invasive Urothelial Carcinoma of the Bladder (MIBC)
Muscle Invasive Urothelial Carcinoma of the Bladder (MIBC)
- Esophageal
Esophageal cancer
- Gastric and Gastroesophageal Junction (GEJ)
Gastric and Gastroesophageal Junction (GEJ)
- Melanoma
Melanoma
- Non-small cell lung (NSCLC)
Non-small cell lung (NSCLC)
- Pancreatic (exocrine only)
Pancreatic (exocrine only)
- Mix of Solid Tumors (MOST)
Mix of Solid Tumors (MOST)
التدخلات
- اختبار تشخيصي blood and tissue samples
routine standard of care
- أخرى blood and tissue samples
Routine standard of care
مقاييس النتائج
مقياس النتيجة الأولي
Blood and tissue biospecimen registry
To establish a blood and tissue biospecimen resource in participants with operable solid tumors, with clinical, lab, radiographic, and pathology annotation for the discovery, development, and validation of MRD assays.
الإطار الزمني Observation from enrollment to 5.5 years after enrollment
التواريخ
| تاريخ البدء | 8 يناير 2025 (فعلي) |
|---|---|
| الإتمام الأولي | 1 ديسمبر 2031 (تقديري) |
| الإتمام | 1 أبريل 2032 (تقديري) |
| أول نشر | 20 سبتمبر 2024 (فعلي) |
| آخر تحديث | 24 سبتمبر 2026 |
| النتائج منشورة | غير مذكور في سجل السجل |
| آخر تأكيد للحالة | سبتمبر 2026 |
فعلي يعني أن الحدث وقع. تقديري يعني أن الجهة الراعية تتوقعه. للكلمتين معنيان مختلفان.
المواقع
47 موقعاً قيد التجنيد
United States
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Piedmont Cancer Institute | Atlanta | Georgia | قيد التجنيد |
| Guthrie Lourdes Memorial Hospital (GLMH) | Binghamton | New York | قيد التجنيد |
| Alabama Oncology | Birmingham | Alabama | قيد التجنيد |
| Mohtaseb Cancer Center and Blood Disorders | Bullhead City | Arizona | قيد التجنيد |
| Gabrail Cancer Center | Canton | Ohio | قيد التجنيد |
| Cancer & Blood Specialists of Arizona | Casa Grande | Arizona | قيد التجنيد |
| Carolina Oncology Specialists | Charlotte | North Carolina | قيد التجنيد |
| Oncology & Hematology Associates of West Broward | Coral Springs | Florida | قيد التجنيد |
| Baptist Health Corbin | Corbin | Kentucky | قيد التجنيد |
| Pontchartrain Cancer Center | Covington | Louisiana | قيد التجنيد |
| Baptist Health Hardin | Elizabethtown | Kentucky | قيد التجنيد |
| The Melanoma and Skin Cancer Institute | Englewood | Colorado | قيد التجنيد |
| San Juan Oncology Associates | Farmington | New Mexico | قيد التجنيد |
| Los Angeles Cancer Network (LACN) | Glendale | California | قيد التجنيد |
| Southeastern Medical Oncology Center (SMOC) | Goldsboro | North Carolina | قيد التجنيد |
| The Cancer & Hematology Centers (CHC) | Grand Rapids | Michigan | قيد التجنيد |
| Onocology Consultants P.A. (Oncology Consultants [OC Houston]) | Houston | Texas | قيد التجنيد |
| Community Clinical Trials | Kingwood | Texas | قيد التجنيد |
| Lancaster General Hospital (UPenn) | Lancaster | Pennsylvania | قيد التجنيد |
| Baptist Health Lexington | Lexington | Kentucky | قيد التجنيد |
| Cancer Partners of Nebraska | Lincoln | Nebraska | قيد التجنيد |
| CARTI | Little Rock | Arkansas | قيد التجنيد |
| Baptist Health Louisville | Louisville | Kentucky | قيد التجنيد |
| Taylor Cancer Research Center | Maumee | Ohio | قيد التجنيد |
| Cancer Care Specialists of Illinois (CCSI) | O'Fallon | Illinois | قيد التجنيد |
| Mid Florida Cancer Centers | Orange City | Florida | قيد التجنيد |
| Ventura County Hematology Oncology Specialists | Oxnard | California | قيد التجنيد |
| Oregon Health & Science University (OHSU) | Portland | Oregon | قيد التجنيد |
| Virginia Cancer Institute | Richmond | Virginia | قيد التجنيد |
| Mayo Clinic | Rochester | Minnesota | قيد التجنيد |
| Medical Oncology Associates of San Diego (MOASD) | San Diego | California | قيد التجنيد |
| Medical Oncology Associates of San Diego | San Diego | California | قيد التجنيد |
| Guthrie Foundation | Sayre | Pennsylvania | قيد التجنيد |
| New York Cancer & Blood Specialists | Shirley | New York | قيد التجنيد |
| Christus Health Highlands | Shreveport | Louisiana | قيد التجنيد |
| Highlands Oncology Group (HOG) | Springdale | Arkansas | قيد التجنيد |
| Cox Health | Springfield | Missouri | قيد التجنيد |
| Comprehensive Hematology Oncology (CHO) | St. Petersburg | Florida | قيد التجنيد |
| Stockton Hematology Oncology Med Group | Stockton | California | قيد التجنيد |
| Northwest Medical Specialties (NWMS) | Tacoma | Washington | قيد التجنيد |
| Christus St. Michael's | Texarkana | Texas | قيد التجنيد |
| Cotton O'Neil Cancer Center [Stormont Vail] | Topeka | Kansas | قيد التجنيد |
| Oklahoma Cancer Specialists and Research Institute (OCSRI) | Tulsa | Oklahoma | قيد التجنيد |
| Carle Health | Urbana | Illinois | قيد التجنيد |
| Cancer Center of Kansas | Wichita | Kansas | قيد التجنيد |
| Regional Medical Oncology Center | Wilson | North Carolina | قيد التجنيد |
| Cancer Care Associates of York (CCAY) | York | Pennsylvania | قيد التجنيد |
مستندات الدراسة
لا تُرتبط أي مستندات في سجل السجل هذا.
التغيّرات عبر الزمن
- 24 سبتمبر 2026
أُضيف موقع
45 sites added (47 total)
247